Drive

Drive is a libido and intimacy stack that works through the brain, not just blood flow. It pairs PT-141 and Oxytocin - two peptides with distinct but complementary mechanisms for desire and connection. PT-141, also known as Bremelanotide or Vyleesi, is a melanocortin agonist. Unlike other approaches to sexual health that focus on blood flow, PT-141 works centrally in the brain to increase sexual desire and arousal. It's FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder, and is used off-label in men. The desire response is genuine - it's not a mechanical effect but a neurological one. It's taken approximately 45 minutes before intimacy, and used on an as-needed basis rather than daily. Oxytocin is the bonding hormone - released naturally during intimacy, physical contact, and social connection. When taken before or during intimate situations, it supports the feelings of trust, closeness, and arousal that PT-141's central desire signal benefits from. Oxytocin is available as an intranasal spray or sublingual formulation, making it easy to use on demand. The Drive stack is for men and women. Women often start PT-141 at the lower end of the dosing range, and the two peptides are used as needed - this is not a daily protocol. PT-141 should not be used more than about twice per week. Side effects to know: PT-141 can cause nausea and a temporary rise in blood pressure, so it requires a cardiovascular review at consult. People with uncontrolled hypertension should not use it. All dosing parameters, timing guidance, and frequency limits are set with a licensed provider in the PepDepo network at your consult.